Abstracts tagged "Pediatric rheumatology"

Abstract Number: 2204 • ACR Convergence 2025
A Novel Framework for Teratogenicity Counseling for Adolescents and Young Adults (AYAs) with Rheumatic Disease on Teratogenic Medications
Brittany Huynh¹, Elizabeth Pfeiffer² and Stacey Tarvin³, ¹Indiana University School of Medicine, Fishers, IN, ²Rhode Island College, Providence, RI, ³Riley Hospital for Children at Indiana University, Indianapolis, IN
Background/Purpose: Prior studies demonstrate low levels of knowledge and reported counseling regarding teratogenicity among AYAs with rheumatic disease. The aim of this study was to…
Abstract Number: 2146 • ACR Convergence 2025
Impact of a Clinical Pathway on Medication Use and Outcomes in Kawasaki Disease
Jonathan Yu¹, Matthew Elias¹, Deborah Whitney¹, Sanjeev Swami¹, Kaylie Shojaie¹, Caroline Burlingame¹, Isabel Armendi¹, Malki Peskin², Melissa Lerman¹, Jerri Miller¹, Jane Lavelle¹, Brandon Ku¹ and Jon Burnham³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Bala Cynwyd, PA, ³Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: Kawasaki disease (KD) is an acute, systemic vasculitis which can lead to coronary artery (CA) aneurysms in young children. In 2018, we developed a…
Abstract Number: 1976 • ACR Convergence 2025
Implementing a Change Package for Depression Screening and Appropriate Response for Children with Rheumatic Disease
Emily Vara¹, Mileka Gilbert¹, Kelly Rouster-Stevens², Talia Buitrago-Mogollon³, Sarah Mabus³, Justin Moore⁴ and Sheetal Vora⁵, ¹Medical University of South Carolina, Charleston, SC, ²Emory University/Children's Healthcare of Atlanta, Peachtree Corners, GA, ³Atrium Health Levine Children’s Center for Advancing Pediatric Excellence, Charlotte, NC, ⁴Wake Forest School of Medicine, Winston Salem, NC, ⁵Atrium Health Levine Children's Hospital, Charlotte, NC
Background/Purpose: Children with rheumatic diseases (RD) are at increased risk for developing mental health (MH) issues, including depression, which can negatively impact disease outcomes. MH…
Abstract Number: 1744 • ACR Convergence 2025
Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus
Ekemini Ogbu¹, Clare Treutel¹, Angela Merritt², Michael Wagner¹ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Childrens Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) affects approximately 1 in 10,000 children in the United States, with the estimated prevalence of childhood neuropsychiatric SLE (NPSLE)…
Abstract Number: 1305 • ACR Convergence 2025
Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study
Nina Shirman¹, Liora Harel², Gil Amarilyo³, Kfir Kaidar⁴, Yonatan Butbul Aviel⁵, Merav Heshin Bekenstein⁶, Mohamad Hamad Saied⁷, Ofra Goldzweig⁸, Adi Miler⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israe, Tel Aviv, Israel, ²Schneider Children's Medical center, Nettnja, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴Pediatric rheumatology, Schneider children's medical center of Israel, Petah Tikva, Israel, ⁵Pediatric rheumatology, Technion Faculty of Medicine, Haifa, Israel, ⁶Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ⁷Carmel Medical Centre, Technion Faculty of Medicine, Haifa, Israel, ⁸Pediatric rheumatology unit, Kaplan medical canter, Rehovot, Israel, ⁹Pediatric rheumatology unit, Technion Faculty of Medicine, Haifa, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is an autoinflammatory disease following SARS-CoV-2 exposure. The optimal treatment strategy remains under investigation, though intravenous immunoglobulin (IVIG)…
Abstract Number: 1287 • ACR Convergence 2025
A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease
Ivan Foeldvari¹, Kathryn Torok², Ozgur Kasapcopur³, Amra Adrovic⁴, Flavio Sztajnbok⁵, Maria Teresa Terreri⁶, Ana Sakamoto⁷, Jordi Anton⁸, Raju Khubchandani⁹, Sindhu Johnson¹⁰, Gülcan Özomay Baykal¹¹, Brian Feldman¹², Dieneke Schonenberg-Meinema¹³, Sujata Sawhney¹⁴, Vanessa Smith¹⁵, Eslam Al-Abadi¹⁶, Simone Appenzeller¹⁷, Stefanie Hajek¹⁸, Maria Katsicas¹⁹, Mikhail Kostik²⁰, Suzanne Li²¹, Hana Malcova²², Anjali Patwardhan²³, Walter Alberto Sifuentes-Giraldo²⁴, Natalia Vasquez-Canizares²⁵, Tadej Avcin²⁶, Patricia Costa Reis²⁷, Siri Opsahl Hetlevik²⁸, Mahesh Janarthanan²⁹, Edoardo Marrani³⁰, Clare Pain³¹, Maria Jose Santos³², Valda Stanevica³³, Sima Abu Alsaoud³⁴, Ekaterina Alexeeva³⁵, Cristina Battagliotti³⁶, Lillemor Berntson³⁷, blanca e r bica³⁸, Jürgen Brunner³⁹, Despina Eleftheriou⁴⁰, Liora Harel⁴¹, Tilmann Kallinich⁴², Dragana Lazarevic⁴³, Kirsten Minden⁴⁴, Dana Nemcova⁴⁵, Susan Nielsen⁴⁶, Farzana Nuruzzaman⁴⁷, Mihaela Sparchez⁴⁸, Yosef Uziel⁴⁹ and Nicola Helmus⁵⁰, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²University of Pittsburgh, Pittsburgh, PA, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Turkey, Turkey, ⁵UFRJ/UERJ, SAO PAULO, Brazil, ⁶UNIFESP, São Paulo, São Paulo, Brazil, ⁷Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil, ⁸Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹Jaslok Hospital and Research Center, Mumbai, India, ¹⁰Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Umraniye Training and Research Hospital, Istanbul, Turkey, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁴Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India, ¹⁵Ghent University Hospital, Gent, Belgium, ¹⁶Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁷Unicamp, Campinas, São Paulo, Brazil, ¹⁸Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ¹⁹Hospital Garrahan, Buenos Aires, Argentina, ²⁰Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²¹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ, ²²Motol University Hospital, Prague, Czech Republic, ²³University of Missouri-Columbia, Columbia, MO, ²⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁵Children’s Hospital at Montefiore, Bronx, NY, ²⁶University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²⁷Hospital de Santa Maria, Lisbon, Portugal, ²⁸Oslo University Hospital, Oslo, Norway, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁰Meyer Children Hospital IRCCS, Firenze, Italy, ³¹Alder Hey NHS Trust, Liverpool, United Kingdom, ³²Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³³Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ³⁴Caritas baby Hospital, Jerusalem, Palestine, ³⁵National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ³⁶Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³⁷Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ³⁸UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ³⁹Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴⁰Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴¹Schneider Children's Medical center, Nettnja, Israel, ⁴²Charite University Medicine Berlin, Berlin, Germany, ⁴³Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ⁴⁴German Rheumatism Research Center, Berlin, Germany, ⁴⁵Charles University, Prague, Czech Republic, ⁴⁶Rigshospitalet, Copenhagen, Denmark, ⁴⁷Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁸Emergency Clinical Hospital for Children, Cluj-Napoca, Romania, ⁴⁹Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁵⁰Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis(jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. In adult systemic sclerosis is interstitial lung…
Abstract Number: 1064 • ACR Convergence 2025
Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry
Hayley M Lynch¹, Jordan E. Roberts¹ and James N. Jarvis², ¹Seattle Children's Hospital/UW, Seattle, WA, ²University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Several studies detail a higher prevalence and severity of juvenile idiopathic arthritis (JIA) in Indigenous North American (INA) children compared to the general population.…
Abstract Number: 0414 • ACR Convergence 2025
Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study
Mariia Pavlenko¹, Mekibib Altaye², Hermine Brunner³, Margaret Chang⁴, Ashley Cooper⁵, Stefanie Davidson⁶, Alexandra Duell³, Bharti Gangwani⁴, Aimee Hersh⁷, Gary Holland⁸, Carl Langefeld⁹, Melissa Lerman¹⁰, Mindy Lo⁴, Virginia Miraldi Utz³, Sampath Prahalad¹¹, Grant Schulert³, Megan Quinlan-Waters¹², Erin Stahl⁵, Edmund Tsui⁸ and Sheila Angeles-Han¹³, ¹Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Boston Children's Hospital, Boston, MA, ⁵Children's Mercy Kansas City, Kansas City, MO, ⁶Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁷University of Utah, Salt Lake City, UT, ⁸UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ⁹Wake Forest University School of Medicine, Winston Salem, NC, ¹⁰Division of Rheumatology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, Philadelphia, PA, ¹¹Emory + Children's Pediatric Institute, Atlanta, GA, ¹²Cincinnati Children's Hospital Medical Center, CCHMC, ¹³Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA) and can lead to vision loss if not detected early. Current clinical…
Abstract Number: 0374 • ACR Convergence 2025
Assessing Attitudes and Barriers to Vaccination in Pediatric Rheumatic
Merav Heshin Bekenstein¹, Rebecca Hetrick², Vidya Sivaraman³, Beth Rutstein⁴, Albert Chow⁵, Peter Chiraseveenuprapund⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁸, guy Brock⁹, Sapuni Chandrasena⁹, Chloé Janse van Rensburg¹⁰ and Marina Gad El Sayed¹¹, ¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ²Indiana University School of Medicine, Indianapolis, IN, ³Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁴The Children's Hospital of Philadelphia, Wynnewood, PA, ⁵Loma Linda University, Loma Linda, CA, ⁶University of Utah, Salt Lake City, UT, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸CARRA, Granville, OH, ⁹The Ohio State University Wexner Medical Center, Columbus, OH, ¹⁰Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada, ¹¹University of California, Riverside School of Medicine, Riverside, CA
Background/Purpose: Vaccine-preventable diseases pose greater risk to children with rheumatic diseases treated with immunosuppressive therapies and to those with underlying immune dysregulation. Despite the importance…
Abstract Number: 2194 • ACR Convergence 2025
Utilizing Case-Based Learning to Teach the Teacher and Improve Health Insurance Literacy
Tyler Reese, Vanderbilt University Medical Center, Madison, TN
Background/Purpose: It is expected that pediatric rheumatology providers prepare adolescent and young adult (AYA) patients to successfully navigate the transition from a pediatric to an…
Abstract Number: 2145 • ACR Convergence 2025
EOS® Imaging System Is a Novel, Rapid, Safe, and Effective Technique To Detect And Assess Calcinosis In JDM
Jessica Perfetto¹, Ciara Maguire², Carli Needle³, Shailee Lala⁴, Vikash Oza² and Philip Kahn⁵, ¹Pediatric Rheumatology, Hassenfeld Children's Hospital at NYU Langone, New York, ²Pediatric Dermatology, Ronald O Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, ³NYU Grossman School of Medicine, New York, ⁴Department of Radiology, NYU Grossman School of Medicine, New York, ⁵Pediatric Rheumatology, Hassenfeld Children’s Hospital at NYU Langone, New York
Background/Purpose: Calcinosis, reported in up to 47% of children with juvenile dermatomyositis (JDM), can cause significant morbidity, including ulceration, infection, and contractures. Given associations of…
Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Sarah McCuaig¹, Julia Rood¹, Em Elliott¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²CHOP, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1742 • ACR Convergence 2025
S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Ganesh Ramanathan¹, Justine Ledochowski², Oscar Mwizerwa³, Tala El Tal⁴, Lawrence Ng⁵, Asha Jeyanathan⁶, Adrienne Davis⁶, Ann Yeh⁶, Linda Hiraki², Deborah Levy², Zahi Touma⁷, Joan Wither⁸, Busisiwe Zapparoli⁹, Ashley Danguecan¹⁰ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹The Hospital for Sick Children, Etobicoke, ON, Canada, ¹⁰Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cognitive impairment is common in childhood-onset systemic lupus erythematosus (cSLE), particularly in domains like executive function and attention. However, attributing cognitive difficulties to brain…
Abstract Number: 1302 • ACR Convergence 2025
Dose Adjustment was Necessary in Patients with Cryopyrin-Associated Periodic Syndrome Switching from Anakinra to Canakinumab
Soyoung Lee and Hyun Kyung Lee, Chung-Ang University Hospital, Seoul, Republic of Korea
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is a spectrum of rare autoinflammatory disorders caused by mutations in the NLRP3 gene, leading to excessive interleukin-1β (IL-1 β)…
Abstract Number: 1284 • ACR Convergence 2025
Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
Daniel Clemente¹, Alina-Lucica Boteanu², Clara Udaondo³, Joan Calzada⁴, Juan Carlos Nieto⁵, Eugenia Enriquez⁶, Inmaculada Calvo⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, Clara Moriano²⁴, Diego Dios¹⁷, Lorena Exposito²⁵, Alicia Garcia²⁶, Laura Martin²⁷, David Fernandez²⁸, Laura Trujillo¹⁴, Anahy Maria Brandy²⁹, CARLOS GUILLEN-ASTETE³⁰ and lydia Abasolo Alcazar³¹, ¹Hospital Infantil Universitario NIño Jesús, Madrid, Madrid, Spain, ²H.U. Ramón y Cajal, Madrid, Spain, ³La Paz University Hospital, Madrid, Spain, ⁴University Hospital Sant Joan de Deu, Barcelona, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Hospital La Fe, Valencia, Comunidad Valenciana, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴Hospital León, LEON, Castilla y Leon, Spain, ²⁵H.U Canarias, Canarias, Spain, ²⁶Rheumatologist, La Laguna, Spain, ²⁷H.R.U Malaga, Malaga, Spain, ²⁸Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ²⁹Hospital Germans Trias i Pujol, Badalona, Spain, ³⁰H.U Ramón y Cajal, Madrid, Spain, ³¹IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in juvenile-onset systemic lupus erythematosus (jSLE) patients. We aimed to assess the…

1
2
3
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].